KLP Kapitalforvaltning AS Acquires New Stake in Progyny, Inc. (NASDAQ:PGNY)

KLP Kapitalforvaltning AS bought a new position in Progyny, Inc. (NASDAQ:PGNY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 35,300 shares of the company’s stock, valued at approximately $609,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of PGNY. Leibman Financial Services Inc. grew its holdings in shares of Progyny by 100.7% in the fourth quarter. Leibman Financial Services Inc. now owns 63,509 shares of the company’s stock worth $1,096,000 after purchasing an additional 31,872 shares during the last quarter. Fort Washington Investment Advisors Inc. OH boosted its position in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company’s stock valued at $25,319,000 after buying an additional 695,740 shares during the period. Clear Harbor Asset Management LLC bought a new position in Progyny in the 4th quarter worth about $989,000. Barclays PLC increased its position in shares of Progyny by 530.4% during the third quarter. Barclays PLC now owns 706,157 shares of the company’s stock worth $11,835,000 after acquiring an additional 594,140 shares during the period. Finally, Baillie Gifford & Co. raised its stake in shares of Progyny by 52.2% during the fourth quarter. Baillie Gifford & Co. now owns 1,332,690 shares of the company’s stock valued at $22,989,000 after acquiring an additional 456,853 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Trading Down 0.5 %

NASDAQ PGNY opened at $22.98 on Thursday. The firm’s fifty day simple moving average is $22.16 and its two-hundred day simple moving average is $18.52. The firm has a market capitalization of $1.96 billion, a P/E ratio of 39.62, a P/E/G ratio of 2.39 and a beta of 1.41. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $36.51.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on PGNY shares. JPMorgan Chase & Co. increased their price objective on Progyny from $17.00 to $23.00 and gave the stock a “neutral” rating in a research note on Tuesday, January 28th. Bank of America increased their price target on Progyny from $21.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, February 11th. Canaccord Genuity Group lifted their price objective on Progyny from $17.00 to $23.00 and gave the company a “hold” rating in a report on Friday, February 28th. Finally, BTIG Research raised shares of Progyny from a “neutral” rating to a “buy” rating and set a $28.00 target price on the stock in a research report on Monday. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Progyny has an average rating of “Hold” and an average target price of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.